Table 1.

Characteristics of Included Trials

Trial	Interventiona	Size of study population	Efficacy outcomes of interest	Baseline blood eosinophil requirement	Study follow up period, weeks
MENSA	Mepolizumab	576	Exacerbation rate, prebronchodilator FEV1, SGRQ score, ACQ-5 score	≥ 150 cells per mcL at screening or ≥300 cells per mcL in previous year	32
MUSCA	Mepolizumab	556	SGRQ score, prebronchodilator FEV1, ACQ-5 score	≥ 150 cells per mcL at screening or ≥300 cells per mcL in previous year	24
DREAM	Mepolizumab	616	Exacerbation rate, prebronchodilator FEV1, ACQ-6 score, AQLQ score	≥300 cells per mcL screening or in the previous year	52
LIBERTY ASTHMA QUEST	Dupilumab	1902	Exacerbation rate, prebronchodilator FEV1	No required minimum	52
PHASE 2B	Dupilumab	776	Exacerbation rate, prebronchodilator FEV1, ACQ-5 score, AQLQ score	No required minimum	24
SIROCCO	Benralizumab	1204	Exacerbation rate, prebronchodilator FEV1, ACQ-6 score, AQLQ score	No required minimum	48
CALIMA	Benralizumab	1306	Exacerbation rate, prebronchodilator FEV1, ACQ-6 score, AQLQ score	No required minimum	56
ANDHI	Benralizumab	656	Exacerbation rate, prebronchodilator FEV1, SGRQ score, ACQ-6 score, CGI-C, PGI-C, SNOT-22, PSIA	≥ 300 cells per mcL at screening or ≥150 cells per mcL with ≥1 of the following: maintenance OCS use, nasal polyposis, ≥3 exacerbations in the previous year, FVC	24

Abbreviations: ACQ, Asthma Control Questionnaire; ANDHI, Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab; AQLQ, Asthma Quality of Life Questionnaire; CALIMA, Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma; CGI-C, Clinical Global Impression of Change; DREAM, Mepolizumab for severe eosinophilic asthma; FEV1, Forced Expiratory Volume in 1 second; FVC, forced vital capacity; LIBERTY ASTHMA QUEST, Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma; mcL, microliter; MENSA, Mepolizumab treatment in patients with severe eosinophilic asthma; MUSCA, Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma; OCS, oral corticosteroid; PGI-C, Patient Global Impression of Change; PHASE 2B, Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial; PSIA, Predominant Symptom and Impairment Assessment; SGRQ, St George’s Respiratory Questionnaire; SIROCCO, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2-agonists; SNOT-22, Sino-nasal Outcome Test

^aAll studies were placebo-controlled